|
ZNF169 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.417899999967E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.76310999999707E-05 |
| Normal-vs-Stage2 |
1.034030E-04 |
| Normal-vs-Stage3 |
1.4927000002718E-07 |
| Normal-vs-Stage4 |
1.59357999999221E-05 |
| Stage1-vs-Stage2 |
9.143200E-01 |
| Stage1-vs-Stage3 |
2.621900E-02 |
| Stage1-vs-Stage4 |
1.577820E-01 |
| Stage2-vs-Stage3 |
1.547220E-01 |
| Stage2-vs-Stage4 |
3.495800E-01 |
| Stage3-vs-Stage4 |
8.735600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.23850000000036E-06 |
| Normal-vs-AfricanAmerican |
7.626800E-04 |
| Normal-vs-Asian |
8.049700E-04 |
| Caucasian-vs-AfricanAmerican |
6.304200E-01 |
| Caucasian-vs-Asian |
1.333020E-01 |
| AfricanAmerican-vs-Asian |
2.290400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.72290000000275E-05 |
| Normal-vs-Female |
8.69520000001955E-07 |
| Male-vs-Female |
2.644600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.74683999999425E-05 |
| Normal-vs-Age(41-60Yrs) |
3.4913999999997E-06 |
| Normal-vs-Age(61-80Yrs) |
1.47829999996851E-06 |
| Normal-vs-Age(81-100Yrs) |
1.193390E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.891600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.869800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.563580E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.797800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.341800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.553400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.004900E-04 |
| Classical-VS-Follicular |
5.824800E-01 |
| Classical-VS-Other |
8.679800E-01 |
| Classical-VS-Normal |
1.58947999999715E-05 |
| Tall-VS-Follicular |
1.977180E-03 |
| Tall-VS-Other |
2.999800E-01 |
| Tall-VS-Normal |
9.30879995308942E-09 |
| Follicular-VS-Other |
9.860000E-01 |
| Follicular-VS-Normal |
1.362880E-04 |
| Other-VS-Normal |
9.302100E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.60016999999346E-05 |
| Normal-vs-N1 |
3.614700E-04 |
| N0-vs-N1 |
7.388400E-01 |
|
|
